Contraception
Volume 81, Issue 3 , Pages 197-201 , March 2010

Sino-implant (II) — a levonorgestrel-releasing two-rod implant: systematic review of the randomized controlled trials

  • Markus J. Steiner

      Affiliations

    • Family Health International, PO Box 13950, Research Triangle Park, NC 27709, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 919 544 7040x11346; fax: +1 919 544 7261.
    • ,
  • Laureen M. Lopez

      Affiliations

    • Family Health International, PO Box 13950, Research Triangle Park, NC 27709, USA
    • ,
  • David A. Grimes

      Affiliations

    • Family Health International, PO Box 13950, Research Triangle Park, NC 27709, USA
    • ,
  • Linan Cheng

      Affiliations

    • Centre for Clinical Research and Training, Shanghai Institute of Planned Parenthood Research (SIPPR), Shanghai 200032, PR China
    • ,
  • Jim Shelton

      Affiliations

    • Bureau for Global Health, United States Agency for International Development, Washington, DC, USA
    • ,
  • James Trussell

      Affiliations

    • Office of Population Research, Princeton University, Princeton, NJ 08544, USA
    • The Hull York Medical School, University of Hull, HU6 7RX Hull, UK
    • ,
  • Timothy M.M. Farley

      Affiliations

    • Department of Reproductive Health and Research, World Health Organization, CH-12211 Geneva 27, Switzerland
    • ,
  • Laneta Dorflinger

      Affiliations

    • Family Health International, PO Box 13950, Research Triangle Park, NC 27709, USA

Received 20 August 2009 ,Revised 30 October 2009 ,Accepted 30 October 2009.

References 

  1. Steiner M. Sino-Implant (II): 2008 Quality assurance evaluation. http://www.infoforhealth.org/implants/sinoimplantqualityeval.pdf(accessed September 28, 2009)
  2. Grimes D. Forgettable contraception. Contraception. 2009;80:497–499
  3. Steiner MJ, Boler T, Obhai G, Hubacher D. Assessment of a disposable trocar for insertion of contraceptive implants. Contraception. 2010;81:140–142
  4. RHInterchange . Global summary of shipments report. Reproductive Health Supplies Coalition. http://rhi.rhsupplies.org/rhi/index.do?locale=en_US(accessed June 4, 2009)
  5. Fang K, Guan Y, Fan H, Gao E, Yang D, Xue L, et al. A multicentre study of CLa implant and Sino-Implant — expanded application (two-year follow-up). J Reprod Contracept. 1997;8:101–110
  6. Higgins JPT, Green SE. Cochrane Handbook for Systematic Reviews of Interventions 5.0.0. [updated Feb 2008]. Available from http://www.cochrane-handbook.org2008;
  7. Fan H, Han L, Jiang J, et al. A multicenter comparative clinical study of Sino-levonorgestrel-releasing implants — No. I and II with Norplant. J Reprod Contracept. 2004;15:101–107
  8. Qi L, Liu J, Yu L, Ye L, Sun L, Liu K. Multicenter clinical study of two Sino-subdermal implants. Chinese J Fam Plann. 2002;79:87–95
  9. Xing Q, Guan Y, Yang D, et al. A multicenter comparative clinical study of two types of Sino-implant. Chinese J Fam Plann. 2002;79:96–104
  10. Du M, Zheng H, Wang Y, et al. Comparative clinical study of Sino-Implant — a levonorgestrel subdermal implant versus Norplant based on four-year observation of 666 cases. J Reprod Contracept. 1998;18:290–294
  11. Guangdong Provincial Panel for Contraceptive Implants . A five-year multi-center observation of three subdermal implants. Guangdong Med J. 2003;24:166–167
  12. Jing X, Shuhua D, Gu X. A five-year comparative clinical study of Chinese No. II implant with Norplant. Chinese J Med. 2002;37:45–46
  13. Fu W. A four-year follow-up observation of Chinese implant for 1000 cases. Suzhou Univer J Med Sci. 2006;26:612–613
  14. He B. Five-year clinical observation of China-made Type-II subcutaneous implant. J Reprod Contracept. 2007;27:80–84
  15. Liu H, Jiang Q, Chen J. A clinical evaluation of long-acting China-made subdermal implants. Jiangsu Med J. 1996;22:796
  16. Liu X, Mao J, Chen X, Wang Z, Jin Y. The safety of Sino-implant — three-year clinical observation. J Reprod Contracept. 1999;10:234–241
  17. Zhang X, Xu Y, Qi L, et al. A six-year observation of clinical application of China-made type II levonorgestrel subdermal implant (Sino-implant). Chinese J Fam Plann. 2000;2:117–122
  18. Zhang Q. Clinical analysis of 1,000 married women with subdermal implants. J Med Theory Prac. 2007;20:1442
  19. Feng J, Yu J, Yang W. Seven-year observation of effectiveness of China-made type II subdermal implant. Chinese Med Res Clin. 2004;2:111–116
  20. Family Planning WHO. A global handbook for providers. Geneva: World Health Organization; 2007;
  21. Jing X, Deng S, Gu Z, Chen G, Wang J. A five-year observation of clinical application of China-made Type II contraceptive subcutaneous implant. Chinese J Fam Plann. 2002;10:282–286
  22. Meirik O, Farley TMM, Sivin I, Diaz S. Post-marketing surveillance of Norplant contraceptive implants: I. Contraceptive efficacy and reproductive health. Contraception. 2001;63:167–186
  23. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Lancet. 2001;357:1191–1194
  24. Xu L, Li J, Zhang M, Ai C, Wang L. Chinese authors do need CONSORT: reporting quality assessment for five leading Chinese medical journals. Contemp Clin Trials. 2008;29:727–731
  25. Wu T, Li Y, Bian Z, Liu G, Moher D. Randomized trials published in some Chinese journals: how many are randomized?. Trials. 2009;10:46
  26. He J, Jin Z, Yu D. Statistical reporting in Chinese biomedical journals. Lancet. 2009;373:2091–2093

☆ FHI is the recipient of grant funding to provide quality testing of Sino-Implant (II) independent of Shanghai Dahua Pharmaceuticals' own QA/QC tests [1], to assist Dahua in identifying distribution partners and to provide technical assistance to distributors in the registration and introduction of the product. Distributors of the product provide a preferential price to the public sector. Dr. Steiner is part of a consulting firm facilitating regulatory approval and product testing of other reproductive health products. Dr. Grimes has consulted with Bayer Healthcare Pharmaceuticals and Schering-Plough, two manufacturers of contraceptive implants.

☆☆ Support for this research was provided by the Bill & Melinda Gates Foundation. The views expressed in this publication do not necessarily reflect those of FHI, the World Health Organization or the funding agency.

PII: S0010-7824(09)00484-3

doi: 10.1016/j.contraception.2009.10.013

Contraception
Volume 81, Issue 3 , Pages 197-201 , March 2010

Article Tools